Overview

Ganetespib, Paclitaxel, Trastuzumab and Pertuzumab for Metastatic Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer

Status:
Completed

Trial end date:
2018-06-01

Target enrollment:

Participant gender:

Summary

This phase I trial studies the side effects and best dose of ganetespib when given with paclitaxel, trastuzumab and pertuzumab in treating patients with human epidermal growth factor receptor 2 positive (HER2+) metastatic breast cancer (MBC).

Phase:

Phase 1

Details

Lead Sponsor:

Memorial Sloan Kettering Cancer Center

Collaborators:

National Cancer Institute (NCI)
New York University Cancer Institute
Synta Pharmaceuticals Corp.

Treatments:

Albumin-Bound Paclitaxel
Mitogens
Paclitaxel
Pertuzumab
Trastuzumab